Hyloris Raises €80m For Business Development
Company Anticipates First European Approval
With the main aim of developing its existing product portfolio and pursuing business development opportunities in the US, Hyloris Pharmaceuticals has successfully raised €80m through a public listing. The company has announced its financial results for the first half of 2020.
You may also be interested in...
Fresh from a successful IPO, Belgian value-added medicines specialist Hyloris Pharmaceuticals has the financial firepower it needs to pursue ambitious expansion plans that include building out a US commercial infrastructure, CEO Stijn Van Rompay tells Generics Bulletin in an exclusive interview.
Value-added medicines specialist Hyloris Pharmaceuticals is launching an IPO to provide the funds it needs to focus on opportunities through the US 505(b)(2) pathway.
Belgian value-added medicines specialist Hyloris Pharmaceuticals says it has raised €15m through a funding round that will give it the firepower to pursue 505(b)(2) applications in the US.